BURWIG SUSAN E sold $13.5M of MEDP

BURWIG SUSAN E (Exec. VP, Operations) sold 20,000 shares of Medpace Holdings, Inc. (MEDP) at $677.00 ($13.54M total) across 2 trades over 2026-10-26 to 2026-10-27.

Original reporting
SEC EDGAR · BURWIG SUSAN E
Published Oct 28, 2026, 8:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 8:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MEDP
Bearish
high confidence
Mentioned
$MEDP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MEDPBearishMed
01

Why it matters

The disclosed sale adds new material information that could affect MEDP's short‑term price dynamics.

02

Market read

Insider sales of this magnitude are noteworthy for traders monitoring biotech stocks.

03

What to watch

No 10b5‑1 plan was in place, suggesting the timing was discretionary.

Relevance 6/10Novelty 8/10Timing: today

Background

Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$MEDPBearishHigh confidence
Context

Executive VP of Operations sold 20,000 shares for $13.54 M via open‑market trades, disclosed in a Form 4 filing.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A $13.5 M sale by a senior officer is material for a mid‑cap biotech and often triggers short‑term selling.

Market effects

May raise concerns for other biotech firms with recent insider sales.

Limited to U.S. biotech investors.

Low; impact confined to MEDP and its peers.

Counterpoint

The sale could be a routine portfolio rebalancing unrelated to company fundamentals.

Key entities

  • BURWIG SUSAN E

    Executive Vice President, Operations at Medpace Holdings.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MEDPMedAI 8/10

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

$MEDPMedAI 8/10

Medpace 3Q 2026: Revenue $716M, EPS $4.84— 10-Q Summary

Medpace Holdings reported Q3 2026 revenue of $716M, up 8.5% YoY, with net income rising 23.7% to $137.46M and EPS increasing 25.4% to $4.84. Growth was driven by Metabolic, Oncology, and CNS services. Nine-month revenue grew 16.9%, net awards reached $873.4M, and backlog increased 5.6% YoY to $3.17B. The company plans organic growth and selective acquisitions.

$MEDPHighAI 8/10

Medpace (MEDP) Q3 2026 Earnings Call Transcript

Medpace (MEDP) reported Q3 2026 revenue of $716M, up 8.5% YoY, with EBITDA of $172.1M (up 16%) and net income of $137.5M (up 23.7%). Guidance raised: revenue $2.835B-$2.855B (12-12.8% growth), EBITDA $638M-$652M (14.4-16.9% growth), EPS $17.97-$18.32. Board approved $1B share repurchase program. Net new business awards up 10.6% QoQ.

$MEDPMed

Medpace Q3 Earnings Call Highlights

Medpace reported a 10.6% year-over-year increase in net new business awards to $873.4 million in Q3, with a total 12-month backlog of $3.02 billion. Ending backlog was $3.2 billion, up 5.6% year-over-year. The company expects $1.99 billion of backlog to convert into revenue over the next year. Management noted shifts in therapeutic mix and strong pending opportunities. Medpace plans to provide 2027 guidance in February, with fourth-quarter awards and cancellations influencing the outlook.

$MEDPHighAI 8/10

Medpace Q3 2026 slides: record awards fuel profit beat, guidance raised

Medpace Holdings (NASDAQ:MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and adjusted earnings of $4.84 per share, exceeding estimates. Net income rose 23.7% to $137.5M, with EBITDA margin widening to 24.0%. The company raised its full-year guidance, citing record new business awards and strong profitability trends. Shares traded near $659.37, close to their 52-week high.